HPV persistence and its oncogenic role in prostate tumors

Journal of Medical Virology

Volumn 84, Issue 10, 2012, Pages 1636-1645

  Tachezy, Ruth ^a   Hrbacek, Jan ^b   Heracek, Jiri ^c   Salakova, Martina ^a   Smahelova, Jana ^a   Ludvikova, Viera ^a   Svec, Alexandr ^d   Urban, Michael ^c   Hamsikova, Eva ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antibodies; DNA; Men; PCR; Prostate cancer; Reservoir

Indexed keywords

ANTIBODY; DNA; ONCOPROTEIN; PROTEIN E6; PROTEIN E7;

ADULT; AGED; ARTICLE; BIOPSY; CANCER PATIENT; CANCER RISK; CARCINOGENIC ACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEROPREVALENCE; UROGENITAL SYSTEM; VIRUS TRANSMISSION;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BIOPSY; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; PROSTATIC NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84865544928     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23367     Document Type: Article

References (46)

1. Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J. 2003. Prostate cancer risk and serologic evidence of human papilloma virus infection: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 12:872-875.
2. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. 1992. Presence of Ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52:5991-5996.
3. Backes DM, Bleeker MC, Meijer CJ, Hudgens MG, Agot K, Bailey RC, Ndinya-Achola JO, Hayombe J, Hogewoning CJ, Moses S, Snijders PJ, Smith JS. 2011. Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. Int J Cancer 130:1888-1897.
4. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. 2010. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:1789-1799.
5. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995. The use of general primers gp5 and gp6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by pcr. J Gen Virol 76:1057-1062.
6. Dennis LK, Lynch CF, Torner JC. 2002. Epidemiologic association between prostatitis and prostate cancer. Urology 60:78-83.
7. Dillner J, Knekt P, Boman J, Lehtinen M, af Geijersstam V, Sapp M, Schiller J, Maatela J, Aromaa A. 1998. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 75:564-567.
8. Evander M, Edlund K, Boden E, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G. 1992. Comparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol 30:987-992.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
10. Gazzaz FS, Mosli HA. 2009. Lack of detection of human papillomavirus infection by hybridization test in prostatic biopsies. Saudi Med J 30:633-637.
11. Gillison ML, Shah KV. 2003. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 31:57-65.
12. Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, Markowitz LE, Smith D, Harris RB. 2007. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: The HPV detection in men study. J Infect Dis 196:1146-1152.
13. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D. 2011. Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 377:932-940.
14. Greer CE, Peterson SL, Kiviat NB, Manos MM. 1991. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 95:117-124.
15. Hernandez BY, Wilkens LR, Zhu X, McDuffie K, Thompson P, Shvetsov YB, Ning L, Goodman MT. 2008. Circumcision and human papillomavirus infection in men: A site-specific comparison. J Infect Dis 197:787-794.
16. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365-1371.
17. Hrbacek J, Urban M, Hamsikova E, Tachezy R, Eis V, Brabec M, Heracek J. 2011. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: A case-control study. BMC Cancer 11:53-63.
18. Hrbacek J, Urban M, Hamsikova E, Tachezy R, Heracek J. 2012. Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review. Urol Oncol Semin Invest.
19. Edge S, Byrd D. 2010a. editors. Compton ceale. Urinary Badder 7th ed. 497-505.
20. Edge S, Byrd D. 2010b. editors. Compton ceale. Prostate 7th ed. 457-468.
21. Lai YM, Yang FP, Pao CC. 1996. Human papillomavirus deoxyribonucleic acid and ribonucleic acid in seminal plasma and sperm cells. Fertil Steril 65:1026-1030.
22. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. 2005. Detection of human papillomavirus DNA and P53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 5:15-22.
23. Leskinen MJ, Vainionp R, Syrjnen S, Leppilahti M, Marttila T, Kylml T, Tammela TL. 2003. Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer. Urology 61:397-401.
24. Lin Y, Mao Q, Zheng X, Yang K, Chen H, Zhou C, Xie L. 2011. Human papillomavirus 16 or 18 infection and prostate cancer risk: A meta-analysis. Ir J Med Sci 180:497-503.
25. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. 1989. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell/Mol Diagn Hum Cancer 7:209-214.
26. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J, Morales-Rodriguez IB, Hernandez-Ordonez MA, Calderon-Cardenas G, Ortiz-Lopez R, Rivas-Estilla AM, Ancer-Rodriguez J, Rojas-Martinez A. 2010. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 10:326-333.
27. Morris BJ, Gray RH, Castellsague X, Bosch FX, Halperin DT, Waskett JH, Hankins CA. 2011. The strong protective effect of circumcision against cancer of the penis. Adv Urol 2011:812368.
28. Noda T, Sasagawa T, Dong Y, Fuse H, Namiki M, Inoue M. 1998. Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res 26:165-169.
29. O'Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, Potts A, Cubie HA, Donaghy M. 2011. HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. Br J Cancer 104:1221-1226.
30. Parker TM, Smith EM, Ritchie JM, Haugen TH, Vonka V, Turek LP, Hamsikova E. 2006. Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors. Oral Oncol 42:288-296.
31. Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, Eschenbach D, Zimmer H, Heilig B, Kopitz J, Pawlita M, Doeberitz MK, Wentzensen N. 2008. Characterization of humoral immune responses against P16, P53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 123:2626-2631.
32. Rintala MA, Pollanen PP, Nikkanen VP, Grenman SE, Syrjanen SM. 2002. Human papillomavirus DNA is found in the vas deferens. J Infect Dis 185:1664-1667.
33. Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. 2009. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 8:879-886.
34. Rotola A, Monini P, Di Luca D, Savioli A, Simone R, Secchiero P, Reggiani A, Cassai E. 1992. Presence and physical state of HPV DNA in prostate and urinary-tract tissues. Int J Cancer 52:359-365.
35. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U. 1999. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 59:823-825.
36. Silvestre RV, Leal MF, Demachki S, Nahum MC, Bernardes JG, Rabenhorst SH, Smith MA, Mello WA, Guimaraes AC, Burbano RR. 2009. Low frequency of human papillomavirus detection in prostate tissue from individuals from Northern Brazil. Mem Inst Oswaldo Cruz 104:665-667.
37. Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP. 2010. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 127:111-117.
38. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA. 2006. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:2160-2166.
39. Svec A, Urban M, Mikyskova I, Tachezy R. 1999. Human papillomavirus in squamous metaplastic epithelium with dysplasia of the epididymis detected by PCR method. Am J Surg Pathol 23:1437-1438.
40. Svec A, Mikyskova I, Hes O, Tachezy R. 2003. Human papillomavirus infection of the epididymis and ductus deferens: An evaluation by nested polymerase chain reaction. Arch Pathol Lab Med 127:1471-1474.
41. Tachezy R, Hamsikova E, Hajek T, Mikyskova I, Smahel M, Van Ranst M, Kanka J, Havrankova A, Rob L, Guttner V, Slavik V, Anton M, Kratochvil B, Kotrsova L, Vonka V. 1999. Human papillomavirus genotype spectrum in Czech women: Correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 58:378-386.
42. Tachezy R, Klozar J, Rubenstein L, Smith E, Salakova M, Smahelova J, Ludvikova V, Rotnaglova E, Kodet R, Hamsikova E. 2009. Demographic and risk factors in patients with head and neck tumors. J Med Virol 81:878-887.
43. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40:779-787.
44. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH. 2010. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 10:862-874.
45. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
46. zur Hausen H. 1996. Papillomavirus infections-A major cause of human cancers. Biochim Biophys Acta 1288:F55-F78.